latanoprost / Generic mfg. - LARVOL DELTA

Efficacy of latanoprost in the treatment of ciliary madarosis. (PubMed, J Fr Ophtalmol) - "This case highlights the potential of latanoprost as a viable treatment for pediatric ciliary madarosis. Further research is warranted to establish guidelines for its off-label use in eyelash loss."

Journal • Glaucoma • Ophthalmology • Pediatrics

Latanoprost for Treatment of Ménière Disease: A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Intratympanic Management for Symptom Control. (PubMed, Otol Neurotol) - "In this placebo-controlled study, latanoprost was not more effective than placebo in the treatment of MD and did not improve speech discrimination in noise, hearing, and tinnitus or vertigo symptoms."

Clinical • Journal • Glaucoma • Ophthalmology • Otorhinolaryngology • Vertigo

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma (clinicaltrials.gov) - P1 | N=37 | Completed | Sponsor: PolyActiva Pty Ltd | Active, not recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ May 2025

Trial completion • Trial completion date • Glaucoma • Ophthalmology

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (clinicaltrials.gov) - P4 | N=35 | Recruiting | Sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Topical Latanoprost for Eyelid Vitiligo: Effective Repigmentation in Two Pediatric Cases. (PubMed, J Cosmet Dermatol) - No abstract available

Journal • Dermatology • Immunology • Pediatrics • Vitiligo

Long-Term Outcome of Endothelial Keratoplasty Among Glaucoma Patients and the Risk of Prostaglandin Analogue (Latanoprost) Use on Graft Rejection. (PubMed, J Clin Med) - "Latanoprost use may further increase the risk of graft rejection by enhancing inflammatory or immune responses. Prospective studies are warranted to confirm these findings."

Journal • Glaucoma • Ophthalmology • Transplant Rejection • Transplantation

Using the Mechanisms of Action Involved in the Pathogenesis of Androgenetic Alopecia to Treat Hair Loss. (PubMed, Int J Mol Sci) - "The goal of AGA treatments is to prevent the hair miniaturization process; however, currently there are only two FDA-approved medications to treat AGA: topical Minoxidil (5% and 2%) for men and women, and oral Finasteride (1 mg tablets-Proscar and Propecia) for men...In this review, we present various treatments that have demonstrated their ability to induce hair growth by controlling the pathophysiological mechanisms involved in the development of AGA. Interestingly, treatment by a combination of some drugs has resulted in better outcomes than each of the drugs alone, hence demonstrating the advantage of activating different molecular mechanisms simultaneously."

Journal • Review • Alopecia • Immunology

When Trials Don't Meet: A Retrospective Statistical Analysis Using Matching-Adjusted Indirect Comparison (MAIC) and Individual Patient Data (IPD) to Compare Catiolanze® With Other Preservative-Free (PF) Latanoprost in Open-Angle Glaucoma (OAG) (ISPOR-EU 2025) - "When a H2H trial is not available, MAIC can supplement NMA. While outcome showed better IOP reduction with Catiolanze®, baseline matching remains a general challenge in MAIC studies. Further analysis is needed to reconfirm the findings."

Retrospective data • Cardiovascular • Glaucoma • Ophthalmology

Impact of preserved and preservative-free latanoprost eye drops on calcium regulation in conjunctival goblet cells (EVER 2025) - No abstract available

Ophthalmology

Long-term evaluation of ocular surface disease signs in patients with open-angle glaucoma or ocular hypertension using the preservative-free 0.005% latanoprost eye drop emulsion: open-label extension data following a 3-month randomized study (EVER 2025) - No abstract available

Clinical • Glaucoma • Ophthalmology

Preservatives in glaucoma treatment: a comparative study of preserved and preservative-free latanoprost eye drops on conjunctival goblet cells (EVER 2025) - No abstract available

Glaucoma • Ophthalmology

Initial efficacy results of Latanoprost 0.005% + Netarsudil 0.02% combination drops, from a single centre (EVER 2025) - No abstract available

Clinical • Ophthalmology

Towards safer glaucoma treatment: cytological evaluation of the conjunctiva in preservative-free vs. preserved latanoprost users (EVER 2025) - No abstract available

Glaucoma • Ophthalmology

Impact of preserved and preservative-free latanoprost eye drops on calcium regulation in conjunctival goblet cells (EVER 2025) - No abstract available

Ophthalmology

Real-world efficacy, safety, and usability of a microvolume eyedrop delivery device in glaucoma: a prospective randomized crossover trial. (PubMed, J Cataract Refract Surg) - "MD delivered with the Nanodropper adaptor provided additional IOP-L, significantly reduced PBE, and decreased the occurrence and severity of non-systemic AEs compared to CD in this cohort of stable POAG/OHT subjects. MD use among glaucoma subjects may enhance tolerability, improve adherence, and long-term IOP control."

Journal • Real-world evidence • Cardiovascular • Glaucoma • Ophthalmology

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost (clinicaltrials.gov) - P4 | N=100 | Completed | Sponsor: Westlake Eye Specialists | Trial completion date: Dec 2025 ➔ Sep 2025 | Trial primary completion date: Dec 2025 ➔ Sep 2025 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Severe Microbial Keratitis Secondary to Prostaglandin-Associated Periorbitopathy. (PubMed, Case Rep Ophthalmol Med) - "Prostaglandin-associated periorbitopathy (PAP) is a known complication of prostaglandin therapy most commonly associated with topical bimatoprost...The authors report a case of PAP-induced lagophthalmos and secondary microbial keratitis that necessitated a corneal graft. Reversal of these findings occurred on prostaglandin cessation with dramatic reversal of findings within 8 weeks."

Journal • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Transplantation

Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Massachusetts Eye and Ear Infirmary | N=31 ➔ 1 | Trial completion date: Dec 2023 ➔ Oct 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jul 2023 ➔ Oct 2025; Low recruitment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Glaucoma • Ophthalmology

The Effect of Preoperative Use of High- vs. Low-PAP-Inducing-Potential FP Agonists on the Surgical Outcomes of Trabeculectomy and AGV Implantation. (PubMed, J Clin Med) - "The eyes were stratified by preoperative FP agonist use into the high-PAP-inducing-potential (bimatoprost or travoprost) and low-PAP-inducing-potential (latanoprost or tafluprost) groups. Although the effect on AGV implantation appears limited, it may still influence early postoperative results. These findings underscore the need to consider PAP risk and medication history when selecting surgical procedures for glaucoma."

Journal • Glaucoma • Ophthalmology

Management of ocular adverse reactions to antiglaucoma medications-Survey of optometrists in Ghana. (PubMed, PLOS Glob Public Health) - "Latanoprost (32.2%), timolol (23.7%), travoprost (17.6%), and brimonidine (10.2%) were the medications most frequently associated with these reactions. These findings highlight that although OADRs are common in glaucoma management, optometrists in Ghana often lack standardized protocols and report low confidence in handling such cases. Targeted professional development and refresher training are needed to strengthen OADRs recognition, reporting, and management, ultimately improving patient eye care."

Journal • Dry Eye Disease • Glaucoma • Ophthalmology

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (clinicaltrials.gov) - P4 | N=35 | Not yet recruiting | Sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,

New P4 trial • Glaucoma • Ophthalmology

Effects of Omidenepag Isopropyl Versus Latanoprost Eye Drops on Intraocular Pressure, Pupil Diameter, and Anterior Chamber Parameters in Normal Feline Eyes: A Pilot Study. (PubMed, Vet Ophthalmol) - "OMDI effectively reduced IOP in cats for at least 4 h without reducing PD. An increase in the CCA and mid-CCW, observed exclusively with OMDI, suggests that the hypotensive effect may be mediated by the conventional outflow pathway. Additionally, an increase in CMT in both the OMDI- and latanoprost-treated eyes may indicate an effect on the uveoscleral outflow pathway."

Journal • Glaucoma • Ophthalmology

Very High Molecular Weight Hyaluronic Acid as an Enhanced Vehicle in Therapeutic Eye Drops: Application in a Novel Latanoprost Formulation for Glaucoma. (PubMed, Bioengineering (Basel)) - "To illustrate these advantages, we examine the pioneering use of a hylan A-based aqueous eye drop formulation as a vehicle to deliver latanoprost, a prostaglandin analogue widely used in the treatment of glaucoma. This case study demonstrates the potential of hylan A-based eye drops to offer safer and more effective topical drug delivery, especially for long-term ocular therapies where tolerability and biocompatibility are critical."

Journal • Review • Glaucoma • Ocular Inflammation • Ophthalmology

Real-world large sample evaluation of drug-related blepharoptosis: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database. (PubMed, Ther Adv Drug Saf) - "Botulinum toxin A, ravulizumab, and latanoprost were found to exhibit the strongest signals...Avelumab and rosuvastatin showed stronger signals for elderly males, while botulinum toxin A and bupivacaine were more significant for younger females. This study validates known associations such as immune checkpoint inhibitors and neuroregulatory agents, and identifies drug-related signals. There are significant differences in the onset times of adverse reactions across drug categories, suggesting the need for targeted monitoring."

Adverse events • Journal • Real-world evidence • Oncology • Ophthalmology • Psychiatry

STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - P3 | N=28 | Terminated | Sponsor: University of Miami | N=500 ➔ 28 | Completed ➔ Terminated; No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint.

Enrollment change • Trial termination • Glaucoma • Ophthalmology